NY-INNOVATIVE-HEALTH
26.8.2021 16:02:07 CEST | Business Wire | Press release
Innovative Health Sciences, LLC (“IHS” or the “Company”) management announced today that IHS has received FDA clearance for its Insignis™ Subcutaneous Needle Sets. This regulatory clearance allows IHS to sell and distribute its subcutaneous needle sets throughout the United States. The FDA clearance comes just weeks after the Company received the CE mark and ISO certifications permitting the sale of the full Insignis™ Syringe Infusion System throughout Europe.
The state-of-the-art Insignis™ Subcutaneous Needle Sets deliver an improved patient experience with reduced pain at a lower cost for the subcutaneous infusion of medications in the home, hospital, ambulatory, or clinic setting. New features include a butterfly-wing channel that maintains the needle at a 90-degree insertion angle, a needle safe-protection design using an audible and tactile wing closure that helps prevent needle stick injuries, and smaller needles. These new Insignis™ Subcutaneous administration sets can be used with typical infusion pump systems cleared for use for the delivery of medications to the subcutaneous tissues.
The 26-gauge subcutaneous needle sets are offered in single, bifurcated, trifurcated, and quad-furcated sets and are offered in 6mm, 9mm, 12mm, and 14mm sizes. “Patients using the Insignis™ needle sets will find that they obtain virtually the same flow as with common 24-gauge needles– but in a smaller, less painful 26-gauge needle,” says Andrew Sealfon, the Company’s Chairman and CTO. “The needle sets are designed and manufactured with features to enhance the patient experience, including the easy to close safety needle design and no-tangle tubing for patient ease of use,” added Sealfon.
The Insignis™ Subcutaneous Needle Sets, available separately, are a subcomponent of the full next generation Insignis™ Syringe Infusion System, which has received CE mark and ISO certifications for European distribution, and is concurrently in process for FDA submission in the United States. The full system includes 5 separate products: infusion pump, IV Controller, (selectable rate flow controller that attaches to a catheter), OneSett™ (subcutaneous selectable rate flow controller combined with subcutaneous needle sets), fixed rate tubing for both intravenous and subcutaneous applications, and subcutaneous needle sets (now cleared for market in the U.S.).
The Insignis™ Syringe Infusion System is the first non-electric infusion pump available with a selectable flow rate controller for both intravenous and subcutaneous routes of administration, providing nearly the performance and accuracy of electronic infusion systems at a fraction of the cost.
Sealfon, Innovative Health Sciences’ founder, is a forty-year investor, innovator, and executive of the medical device industry. Inventor and founder of Repro-Med Systems, Inc. (KORU Medical Systems) and the FREEDOM™ system, Sealfon served as its President, Chairman of the Board, and Chief Executive Officer from September 1982 until July 25, 2018.
About Innovative Health Sciences
New York-based Innovative Health Sciences, LLC provides innovative solutions to the infusion healthcare market. IHS’ approach is patient-centric and future-oriented; our goal is to provide the highest quality of life by empowering the patient to take control of their infusion. For more information on the Company and the products, be sure to check out the new website, www.innohealthsci.com .
Forward-Looking Statements
The statements contained herein are not guaranteed of future performance and undue reliance should not be placed on them. Such Forward-Looking Statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied. These statements are based on management’s beliefs and theory. The Company undertakes no obligation to update Forward-Looking Statements if circumstances or management’s estimates or opinions should change, except as required by applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210826005364/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Arboris Capital Selects ROYC to Expand Private Markets Capabilities on CapGain Platform18.5.2026 09:00:00 CEST | Press release
Arboris Capital Limited (“Arboris”), a DIFC-based firm arranging alternative investments, authorised by the Dubai Financial Services Authority (DFSA), today announced that it has selected ROYC AB (“ROYC”), a private markets technology and infrastructure provider, to support the continued development of its private markets offering through its platform, CapGain. In its ongoing efforts to expand its private markets capabilities across the Middle East, Arboris has undertaken a strategic review of how to further scale its offering while maintaining the integrity of its existing platform. As a result, Arboris has chosen to integrate ROYC’s fund access, sourcing, and structuring capabilities into CapGain, complementing its existing infrastructure. CapGain is Arboris’s proprietary investment platform, purpose-built to facilitate access between international private market opportunities and Professional Investors in the region. CapGain provides fully digital investor onboarding and KYC, a secu
OdysseyRe Announces New Co-Chief Underwriting Officers for EMEA18.5.2026 09:00:00 CEST | Press release
Odyssey Reinsurance Company (OdysseyRe) today announced the appointments of Tegwen Gromellon and Anne-Claire Serres as co-chief underwriting officers of its EMEA division, effective July 1. They succeed longtime Chief Underwriting Officer, Gaël Le Païh, who is retiring later this year following 36 years with the Company. Based in Paris, Serres joined OdysseyRe in 2018 as the market director for France and will lead the division’s business across France, Africa and the Middle East. Gromellon, who joined OdysseyRe in 2004, has served as market director for Germany, Austria, Benelux and Switzerland since 2019. He will take the lead for the rest of Europe, including the relationship with the Company’s representative office in Stockholm for the Nordic markets and across Turkey. “We are delighted to appoint both Tegwen and Anne-Claire to these important leadership positions,” said Isabelle Dubots-Lafitte, chief executive officer of EMEA for OdysseyRe. “These appointments recognize their sign
LogicMonitor and Deutsche Telekom Expand Partnership Across Europe18.5.2026 09:00:00 CEST | Press release
Expanded availability of LogicMonitor within Deutsche Telekom’s managed services portfolio follows successful operational use in the UKSelect outcomes include reduced reporting times and proactive incident preventionExpansion extends across DACH, Benelux, and the Nordics LogicMonitor®, the AI-first platform for Autonomous IT, today announced the expanded availability of its platform within Deutsche Telekom’s managed services portfolio across selected European markets, including DACH, Benelux, and the Nordics. The expansion builds on operational use of LogicMonitor in the United Kingdom since 2023, where it has supported Deutsche Telekom’s service teams in improving visibility across network, cloud, and hybrid infrastructure environments. Experience gained from these deployments is now informing broader service enablement across additional European markets. As enterprise IT environments grow more complex, organisations require more than visibility—they need predictive resilience. Throug
Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy18.5.2026 09:00:00 CEST | Press release
ZH9 is very well tolerated with a favourable safety profile, and no dose-limiting toxicities or Grade ≥3 drug-related adverse events reported.ZH9 demonstrates 91% freedom-from-relapse in NMIBC patients who have reached study end.Company plans to run a larger phase 2 study across a range of patient populations spanning intermediate risk and high risk including CIS. Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting. Prokarium CMO, Dr Josefin-Beate Holz said “These data demonstrate ZH9 as a universally applicable treatment for patients. As the treatment is very well tolerated and is showing impactful outcomes for early a
VahatiCor Appoints Harry D. Rowland, Ph.D., as Chief Executive Officer18.5.2026 08:00:00 CEST | Press release
Endotronix co-founder and former CEO joins VahatiCor as the company advances the A-FLUX Reducer System® and the SERRA-I early feasibility study VahatiCor, Inc., a medtech company developing interventional therapies for Coronary Microvascular Dysfunction (CMD), announced today the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517830314/en/ VahatiCor CEO, Harry D. Rowland, Ph.D. Rowland previously served as Chief Executive Officer and President of Endotronix, where he led the development and commercialization of the Cordella™ Pulmonary Artery Sensor and Heart Failure System. Under his leadership, Endotronix raised over $150 million and grew to more than 150 employees. He also oversaw the PROACTIVE-HF pivotal trial from execution through FDA premarket approval and commercial launch. Following its acquisition by Edwards Lifesciences in 2024, Rowland stayed o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom